Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;1(2):205-214.
doi: 10.2217/hep.13.18. Epub 2014 Mar 20.

Chemoembolization with DC Bead™ for the treatment of hepatocellular carcinoma: an update

Katerina Malagari  1 , Emmanouil Emmanouil  1 , Maria Pomoni  1 , Dimitrios Kelekis  1
Affiliations
Review

Chemoembolization with DC Bead™ for the treatment of hepatocellular carcinoma: an update

Katerina Malagari et al. Hepat Oncol. 2014 Apr.

Abstract

In this review, DC Bead™ for the treatment of hepatocellular carcinoma is discussed. The embolic device and its mechanism of action is described, focusing on the clinical application and the preclinical background. Guidelines for patient selection and management, along with technical considerations for the appropriate use are provided. Clinical details including local response, comparison with conventional chemoembolization and bland embolization, survival and safety issues are also discussed in detail.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1..  Hepatocellular carcinoma in a 58-year-old male with hepatitis B virus liver cirrhosis.
Hepatocellular carcinoma (A) before and (B) after one session of drug-eluting chemoembolization.
See this image and copyright information in PMC

References

    1. Lewis AL, Gonzalez MV, Leppard SW, et al. Doxorubicin eluting beads – 1: effects of drug loading on bead characteristics and drug distribution. J. Mater. Sci. Mater. Med. 2007;18(9):1691–1699. - PubMed
    1. Lewis AL, Gonzalez MV, Lloyd AW, et al. DC Bead™: in vitro characterisation of a drug delivery device for transarterial chemoembolization. JVIR. 2006;17(2):335–342. - PubMed

    2. ▪ Describes basic research and pharmacokinetics.

    1. Biondi M, Fusco S, Lewis AL, et al. New insights into the mechanisms of the interactions between doxorubicin and the ion-exchange hydrogel DC Bead™ for use in transarterial chemoembolization (TACE) J. Biomater. Sci. Polym. Ed. 2012;23(1–4):333–354. - PubMed
    1. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol. 2007;46(3):474–481. - PubMed

    2. ▪ One of the first two studies for human pharmacokinetics.

    1. Poon RN, Tso WK, Pang RW, et al. A Phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin. Gastroenterol. Hepatol. 2007;5:1100–1108. - PubMed

    2. ▪ One of the first two studies for human pharmacokinetics.

LinkOut - more resources